LIMN (Liminatus Pharma, Inc. Class A Common Stock) Stock Analysis - SEC Filings

Liminatus Pharma, Inc. Class A Common Stock (LIMN) is a publicly traded Healthcare sector company. As of May 21, 2026, LIMN trades at $0.29 with a market cap of $8.40M and a P/E ratio of -0.43. LIMN moved -1.21% today. Year to date, LIMN is -72.50%; over the trailing twelve months it is -97.02%. Its 52-week range spans $0.16 to $33.66. Rallies surfaces LIMN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Where can I find LIMN SEC filings?

Rallies organizes LIMN SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.

LIMN Key Metrics

Key financial metrics for LIMN
MetricValue
Price$0.29
Market Cap$8.40M
P/E Ratio-0.43
EPS$-0.43
Dividend Yield0.00%
52-Week High$33.66
52-Week Low$0.16
Volume83.47M
Avg Volume0
Revenue (TTM)$0
Net Income$-10.21M
Gross Margin0.00%

Latest LIMN News

LIMN Analyst Consensus

LIMN analyst coverage data. Average price target: $0.00.

Common questions about LIMN

Where can I find LIMN SEC filings?
Rallies organizes LIMN SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
Does Rallies show LIMN 10-K and 10-Q filings?
Rallies organizes LIMN SEC filing research, including 10-K reports, 10-Q reports, company disclosures, and filing-driven context when available.
Is LIMN research on Rallies investment advice?
No. Rallies provides research, data, and educational context for LIMN. It does not provide personalized investment advice.
LIMN

LIMN